Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors
- 15 February 2005
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (4), 905-909
- https://doi.org/10.1016/j.bmcl.2004.12.062
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Structure-Based Optimization of Novel Azepane Derivatives as PKB InhibitorsJournal of Medicinal Chemistry, 2004
- Novel PI Analogues Selectively Block Activation of the Pro-survival Serine/Threonine Kinase AktJournal of the American Chemical Society, 2003
- Targeting Serine / Threonine Protein Kinase B / Akt and Cell-cycle Checkpoint Kinases for Treating CancerCurrent Topics in Medicinal Chemistry, 2002
- The protein kinase B/Akt signalling pathway in human malignancyCellular Signalling, 2002
- Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinomaEmerging Therapeutic Targets, 2002
- Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responsesOncogene, 2002
- Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMACCurrent Biology, 1998
- Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.Proceedings of the National Academy of Sciences of the United States of America, 1996
- The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1The FASEB Journal, 1995
- Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma.Proceedings of the National Academy of Sciences of the United States of America, 1987